/EPRX
EPRX Stock - Eupraxia Pharmaceuticals Inc.
Healthcare|BiotechnologyNASDAQ
$6.56+4.96%
+$0.31 (+4.96%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.60
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $7.22
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EPRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.49 – $6.63
TARGET (TP)$7.54
STOP LOSS$6.04
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.50
52W High$7.19
52W Low$2.68
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-117,072 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-38,833,335 | $-27,847,229 | $-17,617,452 | $-14,648,928 | $-2,474,569 |
| Net Income | $-36,674,941 | $-28,220,796 | $-18,489,629 | $-18,030,780 | $-4,006,237 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.76 | $-1.17 | $-0.96 | $-1.61 | $-0.31 |
Company Overview
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 67.7% Upside
Now
$9
Low
$11
Average
$12
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 24th 2025 | Cantor Fitzgerald | Initiation | Overweight | $11 |
| June 26th 2025 | H.C. Wainwright | Initiation | Buy | $12 |
| June 16th 2025 | Canaccord Genuity | Initiation | Speculative Buy | - |
| February 21st 2025 | Craig Hallum | Initiation | Buy | $12 |
| November 14th 2024 | Rodman & Renshaw | Initiation | Buy | $9 |
Earnings History & Surprises
EPRXBeat Rate
14%
Last 14 quarters
Avg Surprise
-34.8%
EPS vs Estimate
Beats / Misses
2/12
Last 12 quarters
Latest EPS
$-0.19
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
-23.2%
$-0.21vs$-0.17
Q3 24
-0.4%
$-0.17vs$-0.17
Q4 24
-30.0%
$-0.17vs$-0.13
Q1 25
-16.7%
$-0.21vs$-0.18
Q2 25
-10.5%
$-0.21vs$-0.19
Q3 25
-23.8%
$-0.26vs$-0.21
Q4 25
+17.4%
$-0.19vs$-0.23
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 19, 2026 | $-0.13 | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.13 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.23 | $-0.19 | +17.4% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.21 | $-0.26 | -23.8% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.19 | $-0.21 | -10.5% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.18 | $-0.21 | -16.7% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.13 | $-0.17 | -30.0% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.17 | $-0.17 | -0.4% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.17 | $-0.21 | -23.2% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | — | $-0.15 | — | — |
Q3 2023 | Sep 30, 2023 | $-0.11 | $-0.25 | -124.0% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-0.27 | $-0.36 | -31.0% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.17 | $-0.23 | -34.4% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-0.13 | $-0.41 | -225.8% | ✗ MISS |
Q3 2022 | Sep 30, 2022 | $-0.31 | $-0.22 | +30.0% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-0.30 | $-0.31 | -3.7% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | — | $-0.26 | — | — |
Q4 2021 | Dec 31, 2021 | $-0.27 | $-0.30 | -10.3% | ✗ MISS |
Q3 2021 | Sep 30, 2021 | — | $-0.35 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.41 | — | — |
Latest News
Eupraxia Pharma Announces Second Set Of 52-Week Follow Up Data From Ongoing Phase 1b/2a RESOLVE Trial Evaluating Single Administration EP-104GI For EoE Treatment
📈 PositiveBenzinga•Nov 13, 2025, 10:04 PM
Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:43 PM
Eupraxia Pharmaceuticals Reports Results With 8mg Dose In RESOLVE Trial; Patients In Cohort 9 Experienced The Largest Improvements In Tissue Health Outcomes And Eosinophil Reduction Observed To Date; Expands Phase 2b EP-104GI Study And Plans New GI Indication Trial In 2026
📈 PositiveBenzinga•Sep 29, 2025, 09:03 PM
Eupraxia Pharmaceuticals shares are trading lower after the company announced the pricing of a $70 million offering of 12,727,273 shares at $5.50 per share.
📉 NegativeBenzinga•Sep 23, 2025, 01:24 PM
Reported Earlier, Eupraxia Pharmaceuticals Prices $70M Public Offering Of 12,727,273 Common Shares At $5.50 Each
➖ NeutralBenzinga•Sep 23, 2025, 06:08 AM
Eupraxia Pharmaceuticals Announces Proposed Public Offering Of Common Shares; No Terms Disclosed
➖ NeutralBenzinga•Sep 22, 2025, 08:01 PM
Eupraxia Pharmaceuticals Announces Data From RESOLVE Trial Of EP-104GI In Eosinophilic Esophagitis; At 12 Months, 2/3 Of Cohort 5 Patients Remained In Clinical Remission
📈 PositiveBenzinga•Sep 2, 2025, 12:06 PM
HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $12 Price Target
📈 PositiveBenzinga•Aug 20, 2025, 10:33 AM•Also:
Frequently Asked Questions about EPRX
What is EPRX's current stock price?
Eupraxia Pharmaceuticals Inc. (EPRX) is currently trading at $6.56 per share. The stock has moved +4.96% today.
What is the analyst price target for EPRX?
No analyst price targets are currently available for this stock.
What sector is Eupraxia Pharmaceuticals Inc. in?
Eupraxia Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is EPRX's market cap?
Eupraxia Pharmaceuticals Inc. has a market capitalization of $0.22 billion, making it a small-cap company.
Does EPRX pay dividends?
No, Eupraxia Pharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAARD
Aardvark Therapeutics, Inc. Common Stock
$13.77
Mkt Cap: $0.3B
GNFT
Genfit S.A.
$5.61
Mkt Cap: $0.3B
IVA
Inventiva S.A.
$4.21
Mkt Cap: $0.2B
MDWD
MediWound Ltd.
$18.77
Mkt Cap: $0.2B
NAUT
Nautilus Biotechnology, Inc.
$1.94
Mkt Cap: $0.2B
NTHI
Neonc Technologies Holdings, Inc.
$7.01
Mkt Cap: $0.1B
OBIO
Orchestra BioMed Holdings, Inc.
$4.35
Mkt Cap: $0.2B
RNAC
Cartesian Therapeutics, Inc.
$7.22
Mkt Cap: $0.2B
SLS
SELLAS Life Sciences Group, Inc.
$2.36
Mkt Cap: $0.2B
TARA
Protara Therapeutics, Inc.
$5.27
Mkt Cap: $0.2B
Explore stocks similar to EPRX for comparison